CXRX - Concordia International Corp.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.70
-0.01 (-1.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.71
Open0.71
Bid0.69 x 1000
Ask0.89 x 2000
Day's Range0.68 - 0.72
52 Week Range0.45 - 2.35
Volume30,154
Avg. Volume501,621
Market Cap35.104M
Beta0.52
PE Ratio (TTM)N/A
EPS (TTM)-35.70
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-07-13
1y Target Est0.70
Trade prices are not sourced from all markets
  • CNW Group4 days ago

    Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results

    Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results

  • PR Newswire4 days ago

    Concordia International Corp. Announces Release Date for Fourth Quarter and Year-End 2017 Results

    OAKVILLE, ON, Feb. 21, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to issue its fourth quarter and year-end 2017 financial results via press release before market open on Thursday, March 8, 2018. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward‐looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

  • PR Newswire10 days ago

    Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid

    OAKVILLE, ON, Feb. 15, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it is closing its investigation related to Fusidic Acid eye drops. Fusidic Acid eye drops is a Concordia medicine used to treat conjunctivitis. The CMA notified Concordia in October 2016 that it was investigating some of the Company's products over matters related to pricing.

  • CNW Group10 days ago

    Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid

    Concordia International Corp. Comments on CMA's Decision to Close its Investigation of Fusidic Acid

  • Concordia International Corp. :CXRX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
    Capital Cube2 months ago

    Concordia International Corp. :CXRX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018

    Categories: Yahoo FinanceGet free summary analysis Concordia International Corp. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 154.62 million, Net Earnings of USD -69.49 million. Gross margins narrowed from 51.37% to 36.89% compared to the same period last year, operating (EBITDA) margins now 48.88% from 50.87%. Change in operating ... Read more (Read more...)

  • PR Newswire2 months ago

    Concordia International Corp. Comments on Recent Trading Activity

    OAKVILLE, ON, Dec. 15, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), the Company is confirming that it is unaware at this time of any material change in its operations that would account for the recent increase in market activity. As previously announced, the Company commenced proceedings under the Canada Business Corporations Act (the "CBCA") in an effort to realign its capital structure. The Company continues to advance ongoing discussions with its debtholders in this effort, and is focused on realigning its capital structure on a consensual basis.

  • CNW Group2 months ago

    Concordia International Corp. Comments on Recent Trading Activity

    Concordia International Corp. Comments on Recent Trading Activity

  • CNW Group3 months ago

    Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement

    Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement

  • PR Newswire3 months ago

    Concordia International Corp. Announces Receipt of Nasdaq Initial Notice of Bid Price Requirement

    OAKVILLE, ON, Dec. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that on November 29, 2017, it received an initial notification letter from the Listing Qualifications Department of the NASDAQ Global Select Market ("Nasdaq") notifying the Company that it had 180 days to regain compliance with the minimum bid price requirement set forth in Nasdaq's continued listing rules. Nasdaq's continued listing rules require that listed securities maintain a minimum bid price of US$1.00 per share, and that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • PR Newswire3 months ago

    Concordia International Corp. Comments on CMA Statement of Objections Related to Liothyronine

    OAKVILLE, ON, Nov. 21, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today commented on the issuance by the UK Competition and Markets Authority (the "CMA") of a Statement of Objections ("SO") to the Company and the former owners of the Company's International segment, Hg Capital and Cinven, in relation to the pricing of liothyronine in the United Kingdom between November 2007 and July 2017. A SO is an expression of a preliminary view by the CMA that a competition law infringement may have occurred. The Company has been informed by the CMA that, in relation to the other two products, one has been put on a slower investigative track while the other is not an administrative priority for the CMA currently.

  • CNW Group3 months ago

    Concordia International Corp. Comments on CMA Statement of Objections Related to Liothyronine

    Concordia International Corp. Comments on CMA Statement of Objections Related to Liothyronine

  • Who Are Concordia International Corp’s (TSX:CXR) Major Shareholders?
    Simply Wall St.3 months ago

    Who Are Concordia International Corp’s (TSX:CXR) Major Shareholders?

    Today, I will be analyzing Concordia International Corp’s (TSX:CXR) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...

  • PR Newswire3 months ago

    Concordia International Corp. Announces Third Quarter 2017 Results

    Reported third quarter revenue of $154.6 million Reported third quarter adjusted EBITDA 1 of $78.6 million Generated cash flow from operations of $227.4 million in the first nine months of 2017 Concluded ...

  • CNW Group3 months ago

    Concordia International Corp. Announces Third Quarter 2017 Results

    Concordia International Corp. Announces Third Quarter 2017 Results

  • ACCESSWIRE3 months ago

    Concordia International Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Concordia International Corp. (NASDAQ: CXRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 14, 2017, at 8:30:00 ...

  • CNW Group4 months ago

    Concordia International Corp. Announces Release Date for Third Quarter 2017 Results

    Concordia International Corp. Announces Release Date for Third Quarter 2017 Results

  • PR Newswire4 months ago

    Concordia International Corp. Announces Release Date for Third Quarter 2017 Results

    OAKVILLE, ON, Nov. 1, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2017 financial results before market open on Tuesday, November 14, 2017. The Company will subsequently hold a conference call that same day, Tuesday, November 14, 2017, at 8:30 a.m. ET hosted by Mr. Allan Oberman, Chief Executive Officer, and other senior management. Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries.

  • Newsfile4 months ago

    IIROC Trade Resumption - Concordia International Corp.

    Toronto, Ontario--(Newsfile Corp. - October 20, 2017) - Trading resumes in: Company: Concordia International Corp. TSX Symbol: CXR (all issues) ...

  • CNW Group4 months ago

    Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act

    Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act

  • PR Newswire4 months ago

    Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act

    Canada Business Corporations Act (the "CBCA") is a Canadian corporate statute allowing Canadian corporations to restructure certain debt obligations. OAKVILLE, ON, Oct. 20, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" and together with its subsidiaries, the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has taken a further step in its previously announced efforts to realign its capital structure by commencing a court proceeding under the Canada Business Corporations Act (the "CBCA").

  • Newsfile4 months ago

    IIROC Trade Halt - Concordia International Corp.

    Toronto, Ontario--(Newsfile Corp. - October 20, 2017) - The following issues have been halted by IIROC: Company:  Concordia International Corp. TSX Symbol: CXR (all issues) ...

  • Is It Time To Buy Concordia International Corp (TSX:CXR)?
    Simply Wall St.4 months ago

    Is It Time To Buy Concordia International Corp (TSX:CXR)?

    Concordia International Corp (TSX:CXR), a pharmaceuticals company based in Canada, saw significant share price volatility over the past couple of months on the TSX, rising to the highs of $1.92Read More...

  • CNW Group4 months ago

    Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure

    Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure

  • PR Newswire4 months ago

    Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure

    The Company will use this time to continue its discussions with lenders with the goal of reaching a consensual agreement that would significantly reduce the Company's debt and interest payments to create a financial foundation able to support Concordia's long-term growth.

  • PR Newswire5 months ago

    Concordia International Corp. Announces New Communication With CMA

    OAKVILLE, ON, Oct. 11, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) is investigating new issues in relation to the UK pharmaceutical sector, and that Concordia's International segment and certain of its products are part of the inquiry. The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed. The CMA's investigation includes matters that pre-date Concordia's ownership of the International segment.